Checkpoint Inhibitor Refractory Cancer Market by Type, Application, End-use & Region | Forecast 2023 to 2033
A sharp increase in the global prevalence of several cancers globally is one of the major factors that is anticipated to fuel the growth of the checkpoint inhibitor refractory cancer market during the forecast period.
Checkpoint Inhibitor Refractory Cancer Market Snapshot (2023 to 2033)
The global Checkpoint Inhibitor Refractory Cancer market size is expected to be valued at US$ 38.69 Billion in 2023. With the increasing health concern among people for extended indications of existing immunotherapies, the overall demand for Checkpoint Inhibitor Refractory Cancer is projected to grow at a CAGR of 11.26% between 2023 and 2033, totaling around US$ 112.43 Billion by 2033.
Data Points
Key Statistics
Checkpoint Inhibitor Refractory Cancer Market Value 2023
US$ 38.69 Billion
Checkpoint Inhibitor Refractory Cancer Market Projected Value (2033)
US$ 112.43 Billion
Checkpoint Inhibitor Refractory Cancer Market CAGR (2023 to 2033)
11.26%
According to the analysis of Future Market Insights, the checkpoint inhibitor refractory cancer market is expected to fuel over the analysis period, attributed to the factors such as the growth of a number of FDA approvals for clinical therapy with checkpoints (PD1/PDL1) inhibitors. For instance, six anti-PD-1/PD-L1 mAbs (monoclonal antibodies) have received approval as of December 2020, with additional indications covering 19 different cancer types and two tissue-agnostic diseases. Also, the key developments in the market include the development of monoclonal antibodies for targeted therapeutic approaches.
Additionally, factors such as technological innovations, advancements in cancer screening procedures, and a rise in the prevalence of cancer, are other factors that are projected to propel the demand of the market over the forecast period. Moreover, greater government initiatives to fight cancer, a rise in public awareness, as well as rising healthcare expenses are other factors that will augment the revenue share of the market in the near future. Also, high efficacy and superior treatment outcome-based PD-1/PD-L1 inhibitors are in high demand in severe cancer treatments.
PD-1/PD-L1 Inhibitors market holds nearly 26% market value share of the US$ 140 Billion oncology drugs market in 2021. Further, as early diagnosis remains the cornerstone of cancer control, the rising cancer awareness programs are expected to fuel the support and attention, early diagnosis, as well as treatment as well as palliative care for the population facing cancer diseases.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Checkpoint Inhibitor Refractory Cancer Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Checkpoint Inhibitor Refractory Cancer is projected to increase at a CAGR of 11.26% during the forecast period between 2023 and 2033, reaching a total of US$ 112.43 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.5%.
According to Future Market Insights, a market research and competitive intelligence provider, the Checkpoint Inhibitor Refractory Cancer market was valued at US$ 34.77 Billion in 2022.
The key factors leading to the market growth include the geriatric population across the globe, as well as a rapid increase in the global prevalence of several cancers, mainly in emerging and developed economies, which is expected to boost market growth in the forthcoming years.
For instance, as the World Health Organization reports, cancer has become a primary cause of death globally. As per the updated release of Globocan report released by the International Agency for Research on Cancer (IARC), in December 2020, the global burden of cancer has risen to 19.3 million cases and deaths by cancer have increased to 10 million in 2020. Thus, an upsurge in the volume of the patient pool leads to a greater demand for the market, which is accelerating the growth of the global market during the analysis period.
Leading industry players are focusing on the development and launch of novel PD-1/PD-L1 inhibitors to treat various types of cancers. This escalated the availability of PD-1/PD-L1 immunotherapeutic in the market is expected to boost the checkpoint inhibitor refractory cancer market.
Which Drivers underpin Checkpoint Inhibitor Refractory Cancer Industry Expansion?
Rise in Incidence of Cancer Globallyto Fuel the Market Growth
The rise in the prevalence of cancer around the world is a major factor that will escalate the growth of the global checkpoint inhibitor refractory cancer market in the coming years. For instance, these checkpoint inhibitors are significantly used as front-line treatments for several types of cancer. As per the World Health Organization (WHO), cancer was one of the leading causes of death worldwide, accounting for around ten million deaths in 2020, or nearly one in six deaths. The most common cancers include breast, lung, colon and rectum, and prostate cancers. Thus, there is an increase in demand for checkpoint inhibitors globally.
There are various novel therapies, which have been approved in recent years. In addition, there is a gap between the demand and supply of these therapies, which has led to a huge unmet need. This, in turn, has given vendors an opportunity to conduct studies on drugs such as checkpoint inhibitors. In addition, the increasing approvals of these inhibitors are expected to increase their demand, which is anticipated to fuel the growth of the market.
Increase in Geriatric Population to Accelerate the Market Growth
The rise in cases of the geriatric population globally is projected to fuel the growth of the checkpoint inhibitor refractory cancer market over the analysis period. For instance, as per the Union for International Cancer Control (UICC), the elderly (people aged 65 years and more) are 11 times more likely to develop cancer, when compared to younger people. According to the United Nations, there are over 703 million people aged 65 or older, a number that is expected to reach 1.5 billion by 2050. According to the latest estimates and projections from UN DESA’s Population Division, one in six people in the world will be over the age of 65 by 2050, up from 1 in 11 in 2019.
The rise in research and development activities is expected to offer significant lucrative avenues for players in the checkpoint inhibitor refractory cancermarket. For instance, market players have been increasingly investing in Research and Development activities, in order to meet the increasing demand. For instance, researchers at Johns Hopkins Kimmel Cancer Center are paving the way in developing novel immunotherapies called anti-PD-1 and anti-PD-L1 for people with advanced melanomas. The aim of the therapy is not to kill cancer cells directly, but to block a pathway, that protects tumor cells from components of the immune system that are capable and ready to fight cancer.
An increase in awareness among people about immune checkpoint inhibitors is projected to provide significant growth prospects for players in the global checkpoint inhibitormarket. For instance, with the increase in awareness among people, the demand for these inhibitors is also increasing at a rapid pace globally.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of Checkpoint Inhibitor Refractory Cancer Market?
Stringent Government Regulations to Restrain the Market Growth
Globally, several laws have been introduced to monitor the quality as well as the effectiveness of inhibitors. The regulatory requirements are becoming increasingly stringent, as biologics progress through clinical trials and to commercialization. Due to the nature of biologics, which are produced by living cells, the process and the product must be validated as well as strictly monitored against critical quality attributes (CQAs), throughout the manufacturing process, not just at the end as for chemistry-based drugs. This creates hurdles to getting regulatory approval for the biologics, which in turn is expected to impede the growth of the market.
Further, cancer treatment can cause many side effects, such as depression, tiredness, and trouble eating. The National Cancer Institute and the American Cancer Society describe many of these problems and offer tips for preventing or coping with them. Several side effects can happen months or years after treatment. Hence, the risk of complications associated with the treatment is another factor that will hamper the market growth.
High Cost of Inhibitors to Limit the Market Growth
Cancer treatment costs create significant economic challenges for healthcare providers as well as patients, because of the impact they have on patient safety, quality of care, and overall healthcare. The cost of cancer treatment is high, mainly due to laboratory tests, hospitalization, and the administration of novel checkpoint inhibitors (PD-1 and PD-L1) inhibitor therapeutics. The treatment cost of these therapeutics depends on the stage of cancer. In addition, the high cost is leading to a rise in the preference for alternative treatment options such as surgeries.
For instance, on average, the cost of cancer treatment in India is around INR 503,118 (US$ 6,300) with a minimum expense of INR 90,561 (US$ 1,134) and a maximum cost of INR 27,67,149 (USD 34,650). Also, the cost of available checkpoint inhibitors is high. Thus, the high cost associated with cancer treatment is a major factor that will restrain the treatment adoption rate especially in developing regions.
Region-wise Insights
Will North America Continue Dominance in the Global Checkpoint Inhibitor Refractory Cancer Market?
Favorable Initiatives by Regulatory Authorities in the Region to Fuel the Market Growth
The Checkpoint Inhibitor Refractory Cancer Market in North America is expected to accumulate the highest market share of 39% in 2023.
Factors such as favorable initiatives by the regulatory authorities in the region, especially in the USA, coupled with the increasing prevalence of cancer are expected to boost the growth of the checkpoint inhibitor refractory cancer market in North America. For instance, these inhibitors are used to treat a variety of cancer. As per the American Cancer Society, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the USA. This in turn is anticipated to augment the market’s revenue share in the region.
The USA is estimated to account for around 99.2% of the North America Checkpoint inhibitors market in 2022. The significant share in the US is mainly attributed to the rising incidence of several chronic diseases such as urothelial carcinomas, lung cancers, skin cancer, and diabetes in the region, which demand efficient treatment.
For instance, according to a report from the American Cancer Society (2020), lung cancer is the second leading cancer resulting in 135,720 deaths in men as well as women. The numbers also report that around 84% of all lung cancers are NSCLC (non-small cell lung cancer) and 13% (small cell lung cancer) in the USA, which is expected to continue in the forthcoming years, leading to greater demand for checkpoint Inhibitors thus, fueling the market in the region. The region is expected to hold the highest CAGR of 11.1% during the forecast period.
How Will the Growth of the Checkpoint Inhibitor Refractory Cancer Market unfold in Asia Pacific?
Increasing Government Engagement to Surge Cancer Diagnosis in the Region to Fuel the Market Growth
The Checkpoint Inhibitor Refractory Cancer Market in Asia Pacific is expected to accumulate the highest market share of 37% in 2023.
The regional growth is attributed to the factors such as the high incidence of cancer, growing government engagement to surge cancer diagnosis, and growing adoption of inorganic growth strategies like collaborations, acquisitions, and mergers by major players functioning in the market introduction of new immunotherapies with lesser side effects, and increasing geriatric population in this region, especially in India. For instance, as per the cancer report by the Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with 1.5 million people projected to suffer from the non-communicable disease by 2025, up from 1.39 million in 2020. This is a major factor that will stimulate market growth.
Besides, China is expected to hold a significant growth rate over the analysis period, attributed to factors including a large population base, and major investment from private and public sectors into healthcare infrastructure development. Also, the growing interest in immune checkpoint inhibitors, coupled with the increase in the number of cancer cases, is anticipated to aid the development of the regional market in the near future. The region is expected to hold the highest CAGR of 11.0% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By Application, which Checkpoint Inhibitor Refractory Cancer Category will remain prominent?
Non-Small Cell Lung Segment to beat Competition in Untiring Market
On the basis of type, the global Checkpoint Inhibitor Refractory Cancer market is dominated by the Non-Small Cell Lung Segment, which accounts for a share of 37%. The segment is expected to hold a CAGR of 11.1% over the analysis period.
This significant share of non-small cell lung cancer has encouraged the majority of major players to concentrate on continuous innovation of advanced therapeutics and improving the efficacy of the present therapeutics.
Additionally, a growing number of diagnoses of NSCLC (non-small cell lung cancer), and the rising awareness in the nations of the developing and developed markets are supporting the growth of the non-small cell lung cancer segment.
By End-User, which Checkpoint Inhibitor Refractory Cancer Category dominates?
Hospital Pharmacies Segment to Drive the Checkpoint Inhibitor Refractory Cancer Market
Based on the End-User, the hospital pharmacies segment is expected to witness a significant growth of 48.3% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 11.0% CAGR over the analysis period.
The segment’s growth is attributed to the factors such as large-scale orders, robust supply chains as well as attempts by hospital facilities to sustain large-scale inventories for cancer therapy applications. Moreover, the presence of advanced equipment and the availability of well-developed infrastructure adds to the development of the segment.
Further, the growing patient admission to hospitals for cancer treatment is surging the use of checkpoint inhibitors in hospitals, which in turn is anticipated to accelerate the sales in hospital pharmacies.
The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?
Checkpoint Inhibitor Refractory Cancer Market start-up players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Founded in 2015, ALX Oncology is a developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.
Established in 2015, another start-up named Hummingbird Bioscience is a developer of antibody drugs for cancer treatment. It is involved in developing antibodies by using systems immunology and computational structural biology technology. The company is using platform technology for the design and development of therapeutic antibodies. The pipelined products are HMBD-001 a monoclonal antibody and HMBD-002 an anti-vista monoclonal antibody for cancer treatment.
Founded in 2016, Shattuck Labs is a developer of an immunotherapy platform for oncology and other diseases. The company has developed ARC (Agonist Redirected Checkpoints), which hinges on the development of bispecific biologics that simultaneously block candidate checkpoint molecules in cancer while also stimulating TNF superfamily costimulatory receptors on T cells and innate cells. The company claims that ARC is adaptable to most of the checkpoint targets currently in clinical development.
Who are the Leading Players in the Checkpoint Inhibitor Refractory Cancer Market?
Prominent players in the Checkpoint Inhibitor Refractory Cancer market are Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC., 4D pharma plc., 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, and ENB Therapeutics, Inc., among others.
Recent Developments:
In October 2021, Merck announced the USA Food and Drug Administration (FDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab. The therapy is used for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test.
In January 2020, Novartis International AG acquired The Medicines Company. This acquisition helped Novartis in the treatment of the world’s leading cause of mortality and disability with a vaccine-like approach.
In May 2020, the Food and Drug Administration (FDA) approved Roche’s Tecentriq, as a first-line monotherapy for certain people with metastatic non-small cell lung.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 11.26% from 2023 to 2033
Market Value in 2023
US$ 38.69 Billion
Market Value in 2033
US$ 112.43 Billion
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
Application
End-User
Region
Regions Covered
North America
Europe
Asia Pacific
Rest of the World
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
China
Japan
South Korea
Malaysia
Singapore
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Bristol-Myers Squibb
AstraZeneca
Merck
Genentech/Hoffmann-La Roche
Regeneron Pharmaceuticals
Merck KGaA and Pfizer
Bristol-Myers Squibb
Janssen Research and Development, LLC
4D pharma plc.
4SC AG
OncoSec Medical
Mirati Therapeutics
Ascentage Pharma Group
ENB Therapeutics, Inc.
Exicure, Inc.
Evelo Biosciences, Inc./Merck Sharp & Dohme Corp.
Eisai
Kartos Therapeutics
Exelixis
ImmunityBio
Key Segments Covered in the Checkpoint Inhibitor Refractory Cancer Industry Analysis
Checkpoint Inhibitor Refractory Cancer Market by Type:
PD-1 Inhibitors
PD-L1 Inhibitors
Checkpoint Inhibitor Refractory Cancer Market by Application:
Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-Small Cell Lung Cancer
Others
Checkpoint Inhibitor Refractory Cancer Market by End-User:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Checkpoint Inhibitor Refractory Cancer Market by Region:
North America
Europe
Asia Pacific
Rest of the World
Frequently Asked Questions
What was the market value for Checkpoint Inhibitor Refractory Cancer in 2022?
As of 2022, the market for Checkpoint Inhibitor Refractory Cancer was valued at US$ 34.77 Billion, as per FMI
At what value did the Checkpoint Inhibitor Refractory Cancer Market close in 2023?
By 2023-end, sales of Checkpoint Inhibitor Refractory Cancer closed at a value of US$ 38.69 Billion.
What was the last 4 years value CAGR for Checkpoint Inhibitor Refractory Cancer?
From 2018 to 2022, Checkpoint Inhibitor Refractory Cancer demand expanded at a CAGR of 5.5%
What is the projected forecast CAGR for the Checkpoint Inhibitor Refractory Cancer Industry from 2023 to 2033?
From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%
According to FMI, what is the anticipated market value for Checkpoint Inhibitor Refractory Cancer in 2033?
By 2033, the market value of Checkpoint Inhibitor Refractory Cancer is expected to reach US$ 112.43 Billion.
By Application, which category ranks first with regard to Checkpoint Inhibitor Refractory Cancer?
By Application, the Non-Small Cell Lung segment of the Checkpoint Inhibitor Refractory Cancer constitutes the bulk of the market share of 37% in 2022.
By End-User, which category ranks first with regard to Checkpoint Inhibitor Refractory Cancer?
By End-User, the Hospital Pharmacies segment dominates the market with a share of 48.3% in 2022.
Table of Content
1. Executive Summary | Checkpoint Inhibitor Refractory Cancer Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. CTLA-4 Inhibitor
5.3.2. PD-1 Inhibitor
5.3.3. PD-L1 Inhibitor
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Lung Cancer
6.3.2. Bladder Cancer
6.3.3. Melanoma
6.3.4. Hodgkin Lymphoma
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Type
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Application
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Type
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Application
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Type
13.1.2.2. By Application
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Type
13.2.2.2. By Application
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Type
13.3.2.2. By Application
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Type
13.4.2.2. By Application
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Type
13.5.2.2. By Application
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Type
13.6.2.2. By Application
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Type
13.7.2.2. By Application
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Type
13.8.2.2. By Application
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Type
13.9.2.2. By Application
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Type
13.10.2.2. By Application
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Type
13.11.2.2. By Application
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Type
13.12.2.2. By Application
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Type
13.13.2.2. By Application
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Type
13.14.2.2. By Application
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Type
13.15.2.2. By Application
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Type
13.16.2.2. By Application
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Type
13.17.2.2. By Application
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Type
13.18.2.2. By Application
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Type
13.19.2.2. By Application
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Type
13.20.2.2. By Application
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type
14.3.3. By Application
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. 4D Pharma Plv
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. 4SC AG
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Ascentage Pharma Group
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Eisai Inc
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Bristol-Myers Squibb
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. AstraZeneca
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Merck
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Opdivo
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Keytruda
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Tecentriq
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 13: Global Market Attractiveness by Type, 2023 to 2033
Figure 14: Global Market Attractiveness by Application, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 28: North America Market Attractiveness by Type, 2023 to 2033
Figure 29: North America Market Attractiveness by Application, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 58: Europe Market Attractiveness by Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by Application, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Type, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Type, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033
Figure 88: MEA Market Attractiveness by Type, 2023 to 2033
Figure 89: MEA Market Attractiveness by Application, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
